Drug-likeness prediction of designed analogues of isoniazid standard targeting FabI enzyme regulation from *P. falciparum*

Anil Kumar Pandey¹,², Mohammad Haris Siddiqui¹ & Rajiv Dutta³

¹Department of Bioengineering, Faculty of Engineering, Integral University, Lucknow–226026, India; ²Institute of Bio-Sciences and Technology, Shri Ramswaroop Memorial University, Lucknow Deva Road, Barabanki–225003, India; ³Department of Life Sciences, Faculty of Applied Sciences, Dr. K N Modi University, RIICO Industrial Area Phase-II, Newai, Tonk, Rajasthan - 304021. India. Anil Kumar Pandey - Email: anilpandey1110@gmail.com; Phone: +91 9335487376; *Corresponding author

Received April 1, 2019; Accepted April 10, 2019; Published May 15, 2019

DOI: 10.6026/97320630015364

Abstract:
Fatty acid biosynthesis enzymes (Fab enzyme) are important targets for anti-malarial drug development. The present study describes the toxicity screening of designed novel analogues which inhibit FabI enzyme regulation, a protein with multifunctional property. New analogues were prepared using ChemDraw Ultra 10 Software and converted into 3D PDB structure format for binding studies with FabI (PDB ID: 4IGE). Further Lipinski’s rule of FIVE and ADMET profiling for toxicity prediction has been performed on the designed analogues. The result shows that ISN-23 is potential analogue exhibiting inhibition at the active site of FabI enzyme with good binding features.

Keywords: Lipinski’s rule, ChewDraw, FabI, isoniazid, analogues, malaria

Background:
Malaria is one of the most prominent tropical parasitic diseases [1]. It has been revealed by the World Health Organization (WHO) that around 300–500 million sensitive clinical malarial cases every year and around 1 million deaths do occur every year [1]. Malaria is mainly infected within the poorest populations in the World and it is widely spread in Africa, Asia, and in several South American countries. Malaria is mainly caused by four types of Plasmodium species, but *Plasmodium falciparum* is mainly important for the most serious and deadly form of the disease and is responsible for malaria-related deaths up to 90% in Africa [1]. Medication of malaria is most and wide preference to the National Institutes of Health (NIH) and the significance approaches to the problem calls for multiple steps to tackle this world-wide problem. At present the therapeutic diagnose processes are concentrating in three main areas: (a) vaccine development, (b) drug development, and (c) pathogenesis. Within drug development there is a constant need to develop new drugs to overcome of existing ones for the treatment of malarial infections due to the severe problem of the growing resistance to known and present drugs. There is urgent requirement to identify and characterize the exclusive parasite biochemical pathways which may provide as targets for new drugs, to regulate the mode of action of existing and potential new drugs, and to elucidate possible mechanisms of resistance to existing drugs.

Available drugs respond to three classes of compounds: (1) aryl aminoalcohol compounds eg. quinine (2) antifolates–dihydrofolate reductase inhibitors like pyrimethamine, and (3) Derivatives of...
artemisinin. Artemisinin was first isolated in 1970 by Chinese scientists from Artemisia annua [2, 3]. However, medication with only one drug is not acceptable and now there is a general agreement between scientists that synergistic effects of two drugs probably attempt to the best option for medication which reduces the risk of resistance. Examples of drug synergistic effects are the artemisinin–amodiaquine pair and the artemether–lumefantin [4]. Fatty acids are universal in nature but marine organisms, such as particular sponges, have provided a platform for some of the most interesting varieties based on structure. Most of among these marine fatty acids comes from unusual biosynthetic pathways and excellent reviews have noticed in recent years as the fatty acid varied structure types present in these organisms, their main role in membranes, and their biogenesis processes [5-8]. However, very short is known, or has been revealed, that biomedical potential of these remarkable sponge fatty acids; in particular as to what differences exist in their bioavailability in comparison to reported for the more common fatty acids. Due to present activity in research, we are now able to begin in learning more as to the potential of these marine compounds to conflict of these infectious diseases such as malaria, tuberculosis, and fungal infections. Malaria chemotherapy is an area that is in continuous growth and revision due to the limited number of drugs presently available, the severe side effects of available drugs, and the continuous development of resistance developed by the parasite to some of these drugs [9]. P. falciparum, the malaria parasite of the phylum Apicomplexa which contains an apicoplast, an organelle that originally arise from a cyanobacterium through a process of secondary endosymbiotic and thus shows two membranes [10]. The malaria parasite which contains apicoplast is indispensable for several vital metabolic processes for the parasite do occur at this site. Among these the main processes are isoprene biosynthesis, haem biosynthesis, and fatty acid biosynthesis take place. Higher eukaryotes normally use a type I fatty acid synthase (FAS I) system, where each fatty acid biosynthetic step is catalyzed by a single protein with multiple domains. On the other hand, in the apicoplast a type II fatty acid synthase (FAS II) system is operative, where each fatty acid biosynthetic pathway is carried out towards a discrete enzyme encoded by different gene [11]. In human type II FAS system is absent since we are eukaryotic in nature but is common in bacteria and algae [12]. When the parasite is invading a host it needs to hide itself by creating a parasitophorous vacuole, which imparts a protection of the host immune system. The parasite needs to make its own fatty acids in this process for de novo so as to form its membrane expanded. In P. falciparum the principal membrane fatty acids are decanoic acid (10:0), lauric acid (12:0), and myristic acid (14:0). There are several enzymes responsible for the biosynthesis of fatty acids in P. falciparum which are harmful for human during erythrocytic phase of incubation. Hence, the incorporation of these several enzymes can be inhibited by drugs. Some known drugs are isoniazid (which inhibits FabI), and thio-lactomycin and derivatives (which inhibit FabB and FabF) [13, 14].

The anti-malarial effect of fatty acids has propelled towards deliberation in the past but the realization that fatty acids themselves might inhibit the fatty acid biosynthetic machinery of the parasite P. falciparum has only been presently examined to make strategy towards combating of parasite. It is known that that antimalarial property of n3 and n6 fatty acids which were polyunsaturated in nature postulates the in-vitro invasion of intra erythrocytic forms of P. falciparum [15]. The methyl esters of the fatty acids were reported to be as potent as the free acids in killing the parasite. The binding of the fatty acids to albumin in vivo was also discussed as unlikely to inhibit the anti-malarial effect of the polyunsaturated fatty acids [15].

Methodology:
Target protein structure:
The structures of enzymes (FabI) involved in Plasmodium falciparum regulation was obtained from Protein Data Bank (PDB ID: 4IGE).

Prediction of active sites:
Meta pocket 2.0 Finder was used for several separate procedures to perform active/ binding site prediction (Table 1). To minimize the volume of the box (pocket) enclosing the protein is carried out by generating their coordinates. Every probe coordinates are then clustered according to their spatial proximity, and the full interaction to their energies of probes. This leads to connects all adjacent sites but not on the diagonals of the cube. The probe clusters were ranked according to their total interaction energies, with the most remarkable being identified as the first predicted binding site. The variables for estimation of site volume and identification of proteins / enzymes were predicted by Meta pocket.

Preparation of compounds/analogues:
The 2D-structure of Isoniazid and its 23 analogues were designed by using ACD lab software extension ChemDraw in MDL .mol format.

Drug-likelihood prediction for isoniazid analogues:
The Lipinski rule of FIVE predicts the pharmacological, biological and ADME (absorption, distribution, metabolism and excretion) exercise of the particular compound and also predicting its potentiality to an orally active drug in humans [16].
ADMET analysis for isoniazid analogues:
Using Pre ADMET online server [20] the pharmacokinetics criteria like Adsorption, Distribution, Metabolism, Excretion and Toxicology (ADMET/T) was performed. The properties like Human Intestinal Absorption (% HIA), Caco-2 permeability, MDCK cell Permeability, Skin Permeability, Blood Brain Barrier Penetration and Carcinogenicity all these parameters were deliberated.

**Table 1:** The potential binding sites/active site in FabI (4IGE) using Meta Pocket

| Resi | Gly104 | Ile105 | Gly106 | Asp107 | Asn109 |
|------|--------|--------|--------|--------|--------|
| Resi | Gly110 | Tyr111 | Gly112 | Thr113 | Ser121 |
| Resi | Leu126 | Leu216 | Ala217 | Ala217 | Ser217 |
| Resi | His214 | Lys285 | Ser264 | Asn218 | Ala219 |
| Resi | Val222 | Ala322 | Tyr277 | Ala320 | Met281 |
| Resi | Ile223 | Tyr267 | Phe268 | Ile269 | Thr266 |
| Resi | Pro314 | Ala372 | Asn141 | Lys146 | Phe147 |
| Resi | Ile137 | Phe138 | Arg318 | Val134 | Thr108 |
| Resi | Asp150 | Trp131 | Gly129 | Phe167 | Lys240 |
| Resi | Ala169 | Leu135 | Asp168 | Ser170 | Gly313 |
| Resi | Lys220 | Ala312 | Gln223 | Thr181 | Asn184 |
| Resi | Tyr187 | GLU180 | ASP178 | Pro133 | Phe171 |
| Resi | ASP226 | LYS116 | THR321 | SER239 | SER244 |

**Table 2:** Leads/analogues designed/constructed by taking isoniazid as a standard

| Sr. No. | Canonical SMILE Version |
|---------|-------------------------|
| 1 | C1=CN=C(C(N)=C(O)=N) |
| 2 | C1([H])=C(C(N)=C([H])=C([H])N=C1([H]) |
| 3 | C1([H])=C(C(N)=C([H])=C([H])P=C1([H]) |
| 4 | C1([H])=C(C(N)=C([H])=C([H])=C1([H])P=C1O |
| 5 | C1([H])=C(C(N)=C([H])=C([H])=C1([H])=C1O |
| 6 | C1([H])=C(C(N)=C([H])=C([H])=C1([H])=C1O |
| 7 | C1([H])=C(C(N)=C([H])=C([H])=C([H])=C([H])C=C1O |
| 8 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 9 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 10 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 11 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 12 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 13 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 14 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 15 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 16 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 17 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 18 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 19 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 20 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 21 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 22 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 23 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |
| 24 | C1([H])=C(C(N)=C([H])=C([H])=C([H])C=C1O |

**Results & Discussion:**
Results show that Isoniazid drug inhibit the fabI enzyme regulation during the erythrocytic phase of parasitic incubation. Hence, the active site of FabI enzyme was predicted. Thus, different amino acids residues of the enzymes were found out using meta-pocket 2.0 Finder (Table 1). The residues with potential/active binding sites in FabI (PDB ID: 4IGE) are: Gly104, Ile105, Gly106, Gly110, Tyr111, Trp131, Phe167, Asp168, Ala169, Ser170, Ser215, Leu216, Ala217, Asn218, Leu265, Thr266, Tyr267, Lys285, Ala312, Gly313, Pro314, Leu315, Ser317, Ala319, Ala320, Ile369. The designed analogues (2D structure) were converted into 3D-structures using Discovery Studio 2.5 (Table 2). Further, ADMET as well as drug-likeness were evaluated for the designed analogues. Potential compounds then further examined for their pharmacokinetics properties, metabolism and potential toxicity. Thus, combinatorial chemistry and high throughput ADMET screening were completed. ADMET prediction of analogues was completed using the PreADMET online tool [20] as given in Tables 3 and 4. Drug-likeness of the 23 designed compounds was assessed using the Lipinski’s rule of 5 [17, 18] followed by ADMET evaluation (Table 5). Results show that ISN-23 analogue have the best binding features with FabI enzyme for further in vitro and in vivo consideration.

**Table 3:** Pharmacokinetic studies to measure the drug concentrations in blood or plasma

| Sr. No. | ADMET Properties | Activity Range |
|---------|-------------------|----------------|
| 1. | Human intestinal absorption (HIA) | Poorly: 0–20% |
| 2. | Blood brain barrier (BBB) | CNS active compounds (+): >1 |
| 3. | Heterogenous human epithelial colorectal adenocarcinoma (Caco2) | Moderatse: 25–500 |
| 4. | Plasma protein Binding (% PBP) | Chemicals strongly bound >90% |
| 5. | High Toxity (OR) | Chemicals weakly bound < 90% |

**Abbreviations:** 1) BBB - Blood brain barrier; 2) HIA-Human intestinal absorption; 3) SP-Skin permeability; 4) MDCK- Madin-Darby canine kidney; 5) Caco-2 heterogenous human epithelial colorectal adenocarcinoma; 6) M- mutagen; 7) C-Carcinogen (rat, mouse).

**Table 4:** ADMET prediction of novel designed Analogues with compare to parent compound

| Sr. No. | Lead Name/ Symbol | Caco2 | MDCK | SP | HIA | BBB | Toxicity (M/C) |
|---------|-------------------|-------|------|----|-----|-----|----------------|
| 1. | Isoniazid (Standard) | 9.76 | 0.53 | 5.31 | 82.42 | 0.09 | +/- |
| 2. | ISN-1 | 19.76 | 5.6316 | 2.83253 | 90.82 | 0.24 | +/- |
| 3. | ISN-2 | 19.59 | 4.11 | 4.01 | 73.60 | 0.15 | +/- |
| 4. | ISN-3 | 16.53 | 2.89 | 4.15 | 52.13 | 0.09 | OR |
| 5. | ISN-4 | 13.11 | 1.19 | 4.15 | 30.38 | 0.06 | OR |
| 6. | ISN-5 | 12.02 | 0.97 | 4.00 | 15.73 | 0.05 | OR |
| 7. | ISN-6 | 6.48 | 0.71 | 3.88 | 7.91 | 0.04 | +/- |
| 8. | ISN-7 | 5.69 | 3.34 | 4.33 | 54.55 | 0.54 | +/- |
| 9. | ISN-8 | 1.14 | 2.59 | 4.92 | 33.33 | 0.18 | +/- |
| 10. | ISN-9 | 0.54 | 0.94 | 5.07 | 16.53 | 0.09 | +/- |
| 11. | ISN-10 | 0.53 | 0.71 | 5.08 | 6.95 | 0.06 | +/- |
Table 5: Drug-Likeliness prediction of designed analogues and standard drug

| Sr. No. | Analogues  | MW   | HBA | HBD  | Log P  |
|---------|------------|------|-----|------|--------|
| 1       | Isoniazid (standard) | 137.18 | 3   | 3   | -1.03  |
| 2       | ISN 1      | 151.02 | 4   | 1   | 0.91   |
| 3       | ISN 2      | 167.99 | 3   | 1   | 1.47   |
| 4       | ISN 3      | 183.99 | 4   | 2   | 1.18   |
| 5       | ISN 4      | 199.98 | 5   | 3   | 0.68   |
| 6       | ISN 5      | 215.98 | 6   | 4   | 0.30   |
| 7       | ISN 6      | 231.97 | 7   | 5   | -0.12  |
| 8       | ISN 7      | 251.04 | 5   | 2   | 0.35   |
| 9       | ISN 8      | 167.03 | 6   | 3   | -0.15  |
| 10      | ISN 9      | 183.03 | 7   | 4   | -0.53  |
| 11      | ISN 10     | 199.02 | 8   | 5   | -0.64  |
| 12      | ISN 11     | 138.05 | 3   | 1   | 0.99   |
| 13      | ISN 12     | 154.02 | 3   | 1   | 1.01   |
| 14      | ISN 13     | 197.97 | 3   | 1   | 1.21   |
| 15      | ISN 14     | 245.95 | 3   | 1   | 1.25   |
| 16      | ISN 15     | 202.03 | 7   | 5   | -0.00  |
| 17      | ISN 16     | 218.00 | 7   | 5   | 0.02   |
| 18      | ISN 17     | 261.95 | 7   | 5   | 0.22   |
| 19      | ISN 18     | 309.93 | 7   | 5   | 0.26   |
| 20      | ISN 19     | 170.04 | 5   | 3   | 0.49   |
| 21      | ISN 20     | 186.01 | 5   | 3   | 0.51   |
| 22      | ISN 21     | 229.96 | 5   | 3   | 0.72   |
| 23      | ISN 22     | 285.00 | 4   | 5   | -0.90  |
| 24      | ISN 23     | 128.09 | 2   | 3   | -0.88  |

Abbreviations: 1) Log P= partition coefficient; 2) MW= molecular weight; 3) HBA=hydrogen bond acceptors; 4) HBD=hydrogen bond donor.

Conclusion:
Various designed analogues/compounds are associated with known anti-malarial drugs (isoniazid standard) by clocking FabI enzyme in the treatment of malaria caused by *P. falciparum*. We document the predicted binding of 23 designed analogues with the FabI enzyme and show that ISN-23 analogue have the best binding features with FabI enzyme for further in vitro and in vivo consideration.

References:
[1] Thayer AM, *Chem Eng News* 2005 83:69 [PMID: 18023422]
[2] Klayman DL, *Science* 1985 228:1049 [PMID: 3887571]
[3] Acton N et al. *Planta Med* 1985 47:442 [PMID: 17342606]
[4] Piola P et al. *Lancet* 2005 365:1467 [PMID: 15850630]
[5] Djerassi C et al. *Acc Chem Res* 1991 24: 69 [PMID: 21116406]
[6] Dembitsky VM et al. *Chem Phys Lipid* 2003 123:117 [PMID: 12691847]
[7] Caraballeira NM et al. *Prog Lipid Res* 2002 41:437 [PMID: 12169299]
[8] Berge JP et al. *Adv Biochem Eng Biotechnol* 2005 96:49 [PMID: 16566089]
[9] Thayer AM, *Preventing Malaria. Chem Eng News* 2005 83:85 [PMID: 18023422]
[10] McFadden GI et al. *Nature* 1996 381:482 [PMID: 8632819]
[11] Waller RF et al. *Proc Natl Acad Sci USA* 1998 95:12352 [PMID: 9770490]
[12] Tasdemir D, *Phytochem Rev* 2006 5: 99 [PMID: 20622989]
[13] Heath RJ et al. *Prog Lipid Res* 2001 40:467 [PMID: 11591436]
[14] Jones SM et al. *J Med Chem* 2005 48:5932 [PMID: 16161997]
[15] Kumaratilake LM et al. *J Clin Invest* 1992 89:961 [PMID: 1644925]
[16] Lipinski CA et al. *Adv. Drug Deli. Rev.* 1997 23:3 [PMID: 1682668]
[17] Singh S et al. *Res. J. Pharm. Biol. Chem. Sci.* 2013 4:882 [PMID: 29081608]
[18] Bonate PL et al. *Pharmacokinetics in Drug Development: Regulatory and Development Paradigms. 2004* 1:32 [PMID: 16353932]
[19] http://www.rcsb.org/
[20] http://preadmet.bmdrc.org/

License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License
